Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune DiseasesGlobeNewsWire • 11/08/26
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/26
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/26
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 CongressGlobeNewsWire • 06/03/26
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 05/20/26
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In AutoimmuneSeeking Alpha • 05/14/26
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/26
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual MeetingGlobeNewsWire • 05/14/26
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-celGlobeNewsWire • 04/28/26
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-celBusiness Wire • 04/28/26
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual MeetingGlobeNewsWire • 04/27/26
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ PlatformBusiness Wire • 04/14/26
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 03/23/26
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 03/06/26
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/24/26
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/05/26